Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab Consolidation in Older Patients With Locally Advanced ESCC
NCT07038629Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Sep 2025
- Primary completion
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Sep 2025; status: recruiting.
02
Drugs
iparomlimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07038629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07038629.